Range of surgical procedures1,2
In 15 adult patients with severe VWD, VONVENDI, with or without rFVIII, was used to manage perioperative bleeding in a range of major and minor surgical procedures.1,2
may be all you need to manage perioperative bleeding1
Dosing of VONVENDI® [von Willebrand factor (Recombinant)], with or without recombinant factor VIII (rFVIII), should be based on patient need as determined by monitoring levels and clinical judgment.
factor was all most patients needed2,a
10/15 PATIENTS RECEIVED NO CONCOMITANT rFVIII BEFORE, DURING, OR AFTER SURGERY2
|Vonvendi alone||Vonvendi and rFVIIIb|
|All Surgeries(N=15)||67% n=10||33% n=5|
|Major Surgeries(n=10)||70% n=7||30% n=3|
|Minor Surgeries(n=5)||60% n=3||40% n=2|
dose per day was all most patients needed for postoperative bleeding management2,c
aVONVENDI contains only trace amounts of rFVIII.
bOf the 5 patients who did receive concomitant rFVIII, 2 patients received a preoperative infusion (1 infusion each), 2 patients received a postoperative infusion (1 infusion each), and 1 patient received both one preoperative and 6 postoperative infusions.
cTwo patients undergoing major surgery required more frequent dosing of VONVENDI.
Stay up to date with the latest news and information
Find out about frequency of observed adverse events and the overall safety profile of VONVENDI
Get in touch with a Takeda representative in your area
VONVENDI [von Willebrand factor (recombinant)] is a recombinant von Willebrand factor (rVWF) indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for:
Detailed Important Risk Information
Do not use in patients who have had life-threatening hypersensitivity reactions to VONVENDI or its components (tri-sodium citrate-dihydrate, glycine, mannitol, trehalose-dihydrate, polysorbate 80, and hamster or mouse proteins).
WARNINGS AND PRECAUTIONS
Embolism and Thrombosis
Thromboembolic reactions, including disseminated intravascular coagulation, venous thrombosis, pulmonary embolism, myocardial infarction, and stroke, can occur, particularly in patients with known risk factors for thrombosis, including low ADAMTS13 levels. Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope, and institute prophylaxis measures against thromboembolism based on current recommendations.
In patients requiring frequent doses of VONVENDI in combination with recombinant factor VIII, monitor plasma levels for FVIII:C activity because sustained excessive factor VIII plasma levels can increase the risk of thromboembolic events.
One out of 80 subjects treated with VONVENDI in clinical trials developed proximal deep vein thrombosis in perioperative period after total hip replacement surgery.
Hypersensitivity reactions have occurred with VONVENDI. These reactions can include anaphylactic shock, generalized urticaria, angioedema, chest tightness, hypotension, shock, lethargy, nausea, vomiting, paresthesia, pruritus, restlessness, blurred vision, wheezing and/or acute respiratory distress. Discontinue VONVENDI if hypersensitivity symptoms occur and administer appropriate emergency treatment.
Neutralizing Antibodies (Inhibitors)
Inhibitors to VWF and/or factor VIII can occur. If the expected plasma levels of VWF activity (VWF:RCo) are not attained, perform an appropriate assay to determine if anti-VWF or anti-factor VIII inhibitors are present. Consider other therapeutic options and direct the patient to a physician with experience in the care of either VWD or hemophilia A.
In patients with high levels of inhibitors to VWF or factor VIII, VONVENDI therapy may not be effective and infusion of this protein may lead to severe hypersensitivity reactions. Since inhibitor antibodies can occur concomitantly with anaphylactic reactions, evaluate patients experiencing an anaphylactic reaction for the presence of inhibitors.
In clinical trials, the most common adverse reactions observed in ≥2% of subjects (n=80) were generalized pruritus, vomiting, nausea, dizziness, and vertigo.
One subject treated with VONVENDI in perioperative setting developed deep vein thrombosis after total hip replacement surgery.
Please see VONVENDI full Prescribing Information.